Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized interferon therapy aims to tame kidney disease without weakening defenses

NCT ID NCT05941845

Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial investigates whether a personalized course of peginterferon alfa-2a can control membranous nephropathy, an autoimmune kidney disease. The treatment targets the Th17 inflammatory pathway, which is linked to a higher risk of relapse. Participants receive injections based on their immune profile, with the goal of reducing harmful antibodies and protein leakage without increasing infection risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Peginterferon alfa-2a (Pegasys)
What this could lead to
If successful, this approach could offer a targeted, infection-sparing alternative to standard immunosuppressive treatments for membranous nephropathy.
What could go wrong
This is a very small early-phase trial with only 4 participants, so results may not generalize. Interferon therapy can cause flu-like symptoms and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

4 people

The number who actually took part.

Started

Sep 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 and above 2. Diagnosis of membranous nephropathy PLA2R1 antibodies-mediated 3. Immunological relapse (defined as an increase in anti-PLA2R1 antibody titer \> 14 RU/mL after a phase of anti-PLA2R1 antibody negativation, i.e. immunological remission) 4. Plasma IL-17A levels \> 73 pg/mL after non-specific stimulation of peripheral blood immune cells 5. Symptomatic anti-proteinuric treatment at a stable, maximum-tolerated dosage; 6. Patients with: (i) a platelet count≥ 90,000 cells/mm3; (ii) a neutrophil count ≥ 1500 cells/mm3; and (iii) appropriately monitored normal thyroid function (TSH and T4) at screening Exclusion Criteria: 1. Immunosuppressive treatment for MN in the 6 months before screening 2. Secondary MN (associated with cancer, infectious disease, autoimmune or iatrogenic disease) 3. Active nephrotic syndrome defined according to KDIGO guidelines by proteinuria \> 3.5 g/day (or 3.5 g/g urine sample) and albuminemia \< 30 g/L 4. Absence of previous immunological (anti-PLA2R1 antibodies \< 14 RU/mL in ELISA or negative indirect immunofluorescence) and clinical (partial or complete) remission 5. Patients with a history of thrombosis or treated with anticoagulants 6. Pregnancy or breastfeeding 7. Cancer in treatment 8. Pre-existing retinopathy 9. Active and severe infections 10. Severe liver failure or cirrhosis 11. Pre-existing severe heart failure 12. Pre-existing psychiatric disorder or patient at risk of anxiety or depression (HAD Score \> 11) 13. Patients who use or abuse substances 14. Hypersensitivity to active substance or excipients of study treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Membranous nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Membranous nephropathy

Contacts and locations

Locations

  • CHU de NICE

    Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.